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Abstract
Introduction Variability in response to acetaminophen
(APAP)-induced aseptic inflammation and tolerance to the
impending hepatic damage has been described. To under-
stand the mechanism of adaptive tolerance, we investigated
the proteomic profiles of crude nuclear lysates in a mouse
model. We hypothesized that pretreatment with low doses
of APAP prior to a toxic dose results in differential protein
expression.
Materials and Methods Mice (BALB/C) were separated
into three groups: the pretreated (PT) group received
incremental doses of APAP while the last dose only (LD)
and naïve groups were given saline vehicle. A toxic dose of
APAP was administered on the seventh day to the PT and
LD animals only and all groups were euthanized 3 h
postdose. Total protein from crude hepatic nuclear lysates
were applied to protein arrays and analyzed by immunoaf-
finity mass spectrometry.
Results and Discussion Comparative data analyses of
protein peaks revealed a protein that was significantly
increased at m/z of 60,030 (p60) in the LD animals vs the
other two groups. The closest match for the preliminary
identification of the p60 protein based on a Swiss-Prot/
TagIdent database search using the approximate isoelectric
point and molecular weight information was Ccr4–Not
complex subunit-2. This protein is a subunit of a multi-
protein complex and serves as a transcriptional suppressor
involved in controlling mRNA synthesis and degradation.
Preliminary identification was also supported by Western
blot analysis using anti-CNOT2 antibody.
Conclusion Considering the APAP tolerance model, we
conclude that toxicogenomic approaches such as nuclear
profiling are useful tools in assessing differential expression
of transcriptional factors involved in inflammatory response
and adaptive tolerance to toxins.
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Introduction
Acetaminophen (N-acetyl-para-aminophenol or APAP) is a
commonly available over-the-counter medication. At ther-
apeutic doses, it is an effective analgesic and antipyretic;
however, when consumed in large quantities due to
accidental or deliberate overdose, APAP is the leading
cause of drug-induced acute liver failure [1]. As reviewed
by Gelotte et al. [2], approximately 90% of APAP is
metabolized by two rate-limiting factors. The metabolism
of both glucuronidation via uridine 5′-diphospho-glucuro-
nosyltransferase (isoform UGT1A6) and sulfotransferase
isoforms (SULT1A1 and 1A3) are based upon the avail-
ability of their respective inorganic forms and enzymatic
transferase activities. Roughly 8–10% of APAP is metab-
olized by cytochrome P450 (CYP), a superfamily of
hemoproteins involved in the metabolism of steroid
hormones, drugs, and xenobiotic substances, and the
remaining fraction is excreted unchanged by the kidneys.
The primary cytochrome involved in APAP metabolism,
CYP2E1, results in the formation of a highly reactive and
toxic intermediate N-acetyl-p-benzo-quinone imine
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(NAPQI) that is subsequently metabolized to glutathione by
glutathione-S-transferases. Thiol metabolites of glutathione
production include cysteine, mercapturate, methylthioace-
taminophen, and methyanesulfinylacetaminophen [2] which
are excreted thru the bile or urinary system. In conditions of
APAP overdose and oxidative stress, the primary metabolic
pathway becomes saturated. The reduced glutathione stores
are rapidly depleted and thereby NAPQI accumulates at the
site of metabolism, the liver. As a reactive intermediate,
NAPQI is then free to covalently bind to various intracel-
lular targets, ultimately resulting in hepatocellular injury
and necrosis.
Although the exact mechanism by which APAP exerts
toxicity is not known, it is clear that liver susceptibility to
APAP toxicity is multifactorial. Furthermore, it is yet to be
determined how some individuals tolerate extreme doses of
APAP without exhibiting hepatic toxicity. One such case
was reported by Shayiq and colleagues [3] involving a
patient with an estimated daily ingestion of 65 g of APAP.
While this massive ingestion was thought to have exhibited
extensive hepatic necrosis, permanent liver injury did not
occur. This lack of toxicity may be attributed in part to
inherent variations in CYP2E1 expression [4, 5]. Animal
models have been useful in the studies of complex cellular
responses and networks involved in toxicity. Using these
approaches, induction of tolerance to poisoning brought
about by incremental exposure to multiple sublethal doses
(prior to a lethal dose) have been investigated. To elucidate
the hepatoprotective nature of this exposure, Shayiq et al.
[3] developed a mouse model in which animals were either
pretreated with saline vehicle or administered incremental
sublethal doses of APAP prior to the administration of a
lethal dose. Induced tolerance to APAP was measured in
terms of the median lethal dose (LD-50) or the dose of a
toxic agent necessary to kill 50% of the study population in
a defined time interval. In this study, the LD-50 of the
APAP pretreatment group increased by 400%, suggesting
that pre-exposure afforded hepatoprotection. We have
reproduced this model of adaptive tolerance in our
laboratory and have confirmed tolerance of the pretreated
animals by demonstrating a lack in increased serum alanine
transaminase (ALT) concentrations in the pretreated ani-
mals under APAP dosing conditions that lead to fivefold
increased serum ALT in naïve animals [6].
Proposals for hepatocyte autoprotection (i.e., induced or
adaptive tolerance) include the role of oxidative stress [7–
9], inflammatory chemokines and cytokines [10–12], and
the resultant equilibrium shift in the balance between
proinflammatory and anti-inflammatory cytokines [8, 9].
The investigation of covalent bonding of APAP intermedi-
ates to enzymes and proteins has lead to the examination of
glutathione expression [13] and hepatocyte regeneration
[10, 11, 14].
A variety of standard techniques have been utilized to
assess potential molecular mechanisms of adaptive toler-
ance, including immunohistochemistry [8, 9], RNA, and
protein analyses [14, 15]. Recent technological advance-
ments in proteomic profiling and bioinformatics have
allowed for a dramatic increase in the analyses of
biomarkers in complex biological fluids including: serum
and plasma [16–19], urine [20–23], cellular subfractions
[24–26], ligand binding [27–29], and cerebral spinal fluid
[30, 31]. Although these applications have systematic
limitations [32–34], a variety of platforms are being used
for the separation and identification of novel proteins
involved in various cellular processes.
In an effort to understand and characterize the mecha-
nism of adaptive tolerance, we have utilized proteomic
analyses to evaluate protein expression in crude nuclear
lysates by bioaffinity mass spectrometry. Using a mouse
model of APAP toxicity established in our laboratory [28],
we hypothesized that animals pretreated with low doses of
this drug prior to a final toxic dose differentially express
proteins compared to naïve animals and, as such, these
proteins may contribute to the observed hepatoprotection in
our model system. Understanding the mechanisms for
adaptive tolerance to drugs may provide insights into better
diagnoses and treatments for drug toxicities.
Materials and Methods
Animal Regimen
Animal studies were approved by the University of Louis-
ville Institutional Animal Care and Use Committee
(IACUC). Eighteen male BALB/C mice (The Jackson
Laboratory, Bar Harbor, ME, USA) were randomly divided
into three groups (Fig. 1). Briefly, the last dose only group
(LD) received 0.9% intraperitoneal (i.p.) saline injections
for 6 days and received the lethal dose (350 mg/kg) on the
seventh day. The pretreated group (PT) received incremen-
tal doses of APAP followed by administration of a lethal
dose on the seventh day. The control group (naïve) received
i.p. saline vehicle only for the duration of the study.
Animals were euthanized by cervical dislocation 3 h
postinjection and their liver tissues were immediately
perfused with 5 mL of ice-cold saline, excised, and minced
with scissors in a beaker of ice-cold saline.
Sample Preparation
The saline solution was drained from minced tissue and the
remaining tissue fragments were homogenized in 0.25 M
sucrose buffered with 50 mM potassium phosphate buffer
(pH 7.4). Homogenates were centrifuged at 1,000 rpm in
70 Clin Proteom (2009) 5:69–74
50 mL polycarbonate tubes to sediment cellular debris. The
supernatant was then resedimented at 12,000 rpm for
20 min. Crude nuclear pellets were then aliquoted and
stored frozen at −80°C.
Frozen pellets (approximately 700 μL) were thawed on
ice and combined with approximately 300 μL of auto-
claved, double-distilled ice-cold H2O containing protease
inhibitors (Complete Protease Inhibitors; Roche #1836153;
1:7 dilution, tablet to H2O). The resultant volume was
vortexed briefly and the nuclear suspension (approximately
200 μL) was removed and transferred to 300 μL of U9
buffer (9 M urea, 2% 3-[(3-cholamidopropyl) dimethylam-
monio]propanesulfonic acid, 50 mM Tris–HCl, pH 9.0).
Samples were then vortexed approximately 10 min at room
temperature and then centrifuged at 20,000×g at 4°C for
30 min. The supernatants were collected, aliquoted on ice,
and immediately stored at −80°C [35].
Chip Preparation
Immunoaffinity mass spectrometry products were obtained
from Bio-Rad Laboratories (Hercules, CA, USA) including:
chip arrays, bioprocessors (with disposable reservoirs and
gaskets), sinapinic acid (50% acetonitrile, 0.5% trifluoro-
acetic acid [SPA]) as the energy absorbing molecules
(EAM), PBS-II reader (time of flight mass spectrometer
[TOF-MS]), and the Biomarker Wizard (BW) software. The
performance of the mass spectrometer was monitored
weekly by assessing its calibration according to the
manufacturer’s instructions.
Multiple chip arrays were utilized to capture proteins
based upon their innate biochemical properties, including
IMAC30 (metal binding), SAX2 (strong cation exchange),
and H4 (hydrophobic) surfaces. Chips were processed in
96-well formatted bioprocessors. The IMAC30 chip surface
required activation by the addition of 100 mM CuS04; the
addition of 100 mM of sodium bicarbonate (pH 4.0)
facilitated the removal of any remaining unbound copper
molecules. All chip types were equilibrated with their
respective binding/washing buffers according to the manu-
facturer’s instructions. Binding/washing buffers for
IMAC30 (100 mM NaH2PO4 [pH 7.0], 0.5 M NaCl, 0.1%
polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl
ether [Triton X-100]), SAX2 (10 mM Tris Base [pH 8.0],
0.1% Triton X-100) and H4 (50 mM 1 mM N-(2-
hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid [HEPES
buffer, pH 7.0], 0.1% Triton X-100) surfaces were applied
to the chip surface prior to protein application.
Protein concentration was determined using the Bradford
Assay (Bio-Rad Laboratories, Hercules, CA, USA) using
albumin as the standard (Sigma-Aldrich [purity of 96% by
electrophoresis]). Crude nuclear lysates (15 μg in 2:3 [v/v]
of deionized water/U9 buffer) were incubated on chip
surfaces for 30 min followed by repeated washes with each
chip’s respective buffer. All chips were washed with 1 mM
HEPES buffer (pH 7.0) prior to bioprocessor disassembly.
Excess volume was drained from each chip spot and arrays
were air-dried. The EAM for each chip type was SPA and
was applied in two successive 1-μL aliquots. Experimental
groups were analyzed concurrently to minimize chip to chip
variation using the Bio-Rad Laboratories PBS-II protein
chip reader. Samples were randomized on each chip and run
in triplicate.
Initially, all spectra were visually inspected. If the matrix
peaks were missing or depressed below 30% the log-
normalized value, the spectra were eliminated from final
data analysis. Peaks were detected with first and second
pass signal to noise ratio of 5 and 2 using the BW software.
All spectra were normalized according to manufacturer’s
instructions. Calculated p values using the BW software
were utilized in selecting proteins which yielded the
greatest mass difference amongst groups. The mass of
relevant peaks were further analyzed using the ExPASy
molecular biology server (http://ca.expasy.org/tools/tagi
dent.html; accessed on March 2005) to ascertain potential
protein candidates. Input variables included a percentage
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Fig. 1 APAP dosing regimen. The naïve group was treated with
saline vehicle only. The pretreated group (PT) was incrementally
administered various doses of APAP followed by a lethal dose. The
last dose only animals (LD) were treated with saline followed by a
final lethal dose of APAP
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(pI), range of the protein (as estimated by the pH of the
binding and wash buffer solutions for each chip type),
organism classification (i.e., mouse), and keyword (restrict-
ed based on UniProtKB list of keywords).
Western Blot
Mouse liver crude nuclear lysates (15 μg per lane) were
loaded onto 4–20% gels (Bio-Rad Laboratories, Hercules,
CA, USA) prior to sodium dodecyl sulfate polyacrylamide
gel electrophoresis. Gels were transferred to nitrocellulose
membrane using the Semi-Dry Trans-Blot Apparatus (Bio-
Rad Laboratories, Hercules, CA, USA) according to
manufacturer’s instructions. Following an initial block
(5% dried milk in 1X phosphate buffered saline, 137 mM
NaCl, 10 mM phosphate, 2.7 mM KCl, pH 7.4) and
multiple washes (1X phosphate buffered saline plus 0.005%
Tween-20), membranes were hybridized with a rabbit
antihuman IgG polyclonal antibody to CNOT2 using a
1:500 dilution in blocking buffer (affinity purified recom-
binant protein, confirmed by immunohistochemistry and
Western blotting [ProteinTech Group, Chicago, IL, USA])
[35]. Membranes were then washed with agitation for
30 min and subsequently hybridized with a goat antirabbit
IgG-labeled HRP antibody diluted 1:2,000 in blocking
buffer (Abcam, Cambridge, MA, USA). Chemiluminescent
signal was detected by Enhanced Chemiluminescent Plus
reagents according to the manufacturer’s recommendations
(Amersham Biosciences, Piscataway, NJ, USA) and ex-
posed to chemiluminescence film.
Results and Discussion
Crude hepatic nuclear lysates from the three experimental
conditions (i.e., naïve, PT, LD) were analyzed on IMAC30,
H4, and SAX2 chip types. The ranked p values for the
detected peaks (as calculated by the BW software) for all
chip types were analyzed in order to select proteins that
were significantly altered with the most probable differ-
ences amongst the groups. For example, proteins scanned
between m/z 1,643 and 125,128 on the SAX2 chip yielded
65 protein peaks. Since it would have been exhaustive to
identify all peaks from the three chips with signal to noise
ratios >3, we only pursued peaks with p values ≤0.05 for
comparison among experimental groups (Table 1). Peaks
that were significantly different were further queried using
the Swiss-Prot database for potentially relevant nuclear
protein candidates (transcription factors) involved in adap-
tive tolerance.
Our investigations lead us to focus primarily on the
SAX2 chip protein peaks. We chose to concentrate on the
preliminary identification steps for one particular protein
with a m/z of 60,030 Da (p60). The p60 protein was
significantly increased in the LD (Fig. 2), which exhibited
the greatest toxicity after the final dose of 350 mg/kg APAP
(p value=0.0006). The p60 protein in animals receiving the
LD was also significantly increased (p value=0.0032) when
compared to the naïve group. Interestingly, this protein was
not significantly different between the naïve and the PT
group (p value=0.1278).
Tentative protein identification via the ExPASy Swiss-
Prot/TagIdent database allowed for the incorporation of pI,
MW, organism classification, and a set of predefined key
words. Since this protein had been discovered using the
SAX2 chip type with a binding/washing buffer with a pH
Table 1 Analyses of chip types vs treatment groups
Group Chip type
SAX2 IMAQ H4
LD vs PT 23 10 20
Naїve vs PT 7 5 19
LD vs Naїve 6 2 7
Chip types included: IMAC30 (metal binding), SAX2 (strong cation
exchange), and H4 (hydrophobic) surfaces. Treatment groups includ-
ed: naïve (saline vehicle only), LD (saline vehicle/last dose only), and
PT (pretreatment with incremental doses of APAP followed by a lethal
























Fig. 2 Comparison of peaks (height from baseline) for the three
groups. The height from baseline of the p60 protein was significantly
different between the PT and LD groups (p=0.0006) but not between
the naïve and PT animals (p=0.13). Standard deviations are shown
1          2          3               4            5            6             7             8
60kDa
Fig. 3 The p60 protein analyses by Western blot. We verified the
putative match by using antibody specific to the Ccr4–Not transcrip-
tion complex subunit-2 protein. Lane 1 the positive control (HeLa
cells), lane 2 the MW standards. Independent samples are depicted for
naïve (lanes 3–4), pretreated (lanes5–6), and last dose only (lanes 7–
8) animals. The negative control did not contain any bands and is not
shown. These results indicate that the CNOT2 protein is differentially
expressed, consistent with mass spectrometry data
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of 8.0, the following specifications were used as search
criteria: MW of 60.030±600, pI equal to 8.0±1.0, and
organism classification defined as mouse. The ExPASy
Swiss-Prot database resulted in 39 possible matches.
Elimination criteria included proteins not expressed in the
nucleus and from tissues other than the liver. The carbon
catabolite repressor 4-negative on TATA-less genes (Ccr4–
Not transcription complex) subunit-2 was determined to be
the best fit and closest partial identification for this protein
based on the pI (7.61), MW (59,711), and organism
classification (mouse).
The NOT genes were originally isolated in yeast [36, 37]
by genetic screening and identified as negative regulatory
elements of transcription on TATA-less promoters (HIS3
gene; S. cerevisiae). The CNOT2 gene, a member of the
CNOT 2/3/5 family, is located on chromosome
10:115889276–115985621 bp, − strand (GeneID: 72068)
in mice (Cnot2) and on 12q15 (GeneID: 4848) in humans
(CNOT2). There are two forms of the Ccr4–Not complex
(1.0 and 1.9 MDa forms) as determined by mass spectrom-
etry [38]. As reviewed by Denis and Chen [39], the roles of
the Ccr4–Not transcriptional complex include the repres-
sion and activation of mRNA initiation, mRNA elongation,
deadenylation, and degradation. This complex signaling
network can function individually or synergistically to
initiate various functions [39] and is located in both in the
nucleus and cytoplasm [40]. Polymorphisms are known to
influence transcriptional activity; human CNOT2 has
approximately 300 single-nucleotide polymorphisms/var-
iants as identified by Applied Biosystems (Foster City, CA,
USA; http://www.genecards.org/cgi-bin/carddisp.pl?gene=
CNOT2), while the mouse (Mus musculus) has eight
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=
72068).
To further test the validity of the preliminary identity of
the p60 protein being CNOT2, we purchased a commer-
cially available anti-CNOT2 polyclonal antibody. Prelimi-
nary Western blot results from independent animal samples
from naïve, PT, and LD mice (Fig. 3) resulted in cross-
reactivity of multiple bands. As the Ccr4–Not complex
contains many proteins that span a defined MW region, we
anticipated cross-reactivity consistent with those previously
reported by Winkler et al. [40]. However, the p60 protein
illustrated a trend toward an increased expression in the LD
group compared to the naïve and PT mice. These results are
consistent with the mass spectrometric findings (above) in
that the naïve and PT protein levels did not significantly
differ from each other but their protein expression was
lower than the LD group (Fig. 2). Together, these findings
are consistent with the lack of APAP toxicity in PT animals
as measured by serum ALT concentrations [6]. It appears
that the PT animals developed an adaptive tolerance to
APAP due to the incremental dosing over the experimental
period. Interestingly, without pretreatment, the LD group
exhibited widespread hepatic inflammation and necrosis
[41].
Our preliminary identification of this protein as CNOT2
suggests that its expression may ultimately result in
regulatory factors that mediate APAP-induced hepatic
inflammation. Inflammation of major organs such as the
liver and kidneys is the primary means by which APAP
exerts its initial toxic effects [6, 42, 43]. In APAP poisoning
cases, it takes 2–3 days on average for hepatic inflamma-
tion and damage to appear clinically. The finding that the
CNOT2 protein was expressed similarly in the naïve and
PT animals implies a potential role for this transcriptional
factor in adaptive APAP tolerance. It is clear from the
animal model that proinflammatory cytokines play a major
role in APAP adaptive tolerance [11, 44–47]. Identification
of the p60 protein via proteomic technology has augmented
our knowledge of the potential key players in aseptic
inflammation. The involvement of a transcriptional factor
regulating gene expression in adaptive APAP tolerance is
suggestive of transcriptional control as a regulatory mech-
anism of autoprotection.
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